Historical mrna News Stories
Moderna Stock Rally: Costs, Guidance, Funding Hit!
Moderna (MRNA) recently posted a sharp stock rally after reaffirming conservative revenue guidance and outlining cost-cutting targets at the J.P. Morgan Healthcare Conference. Strong technical indicators contrasted with a U.S. $500M cut to public mRNA research funding — a development that raises execution risk for Moderna’s therapeutic programs even as vaccine commercialization efforts move forward.
Moderna Spike: mRNA-1010 Filings Propel Stock Rise
Moderna’s shares jumped after the company filed mRNA-1010 seasonal flu vaccine applications across major regulators. The coordinated filings and clearer commercialization pathway pushed investor sentiment higher, signaling a strategic shift beyond COVID-19 products.
Moderna Gains: $54M CEPI Deal, RS Rating Up
Moderna (MRNA) received $54.3M from CEPI to support a Phase 3 bird‑flu vaccine trial and saw a modest IBD Relative Strength upgrade. These developments reduce program risk and improve technical price momentum, though revenue declines and execution milestones remain key near‑term drivers for the Nasdaq‑100 stock.
Moderna Rally: EMA Nod and Technical Breakout 2025
Moderna gained momentum after the EMA's CHMP gave a positive opinion on its next-gen COVID candidate mNEXSPIKE and technical indicators flagged a potential breakout. Investors should weigh near-term catalysts against weak recent fundamentals and growing sector consolidation.
Moderna Secures CEPI Grant; Shares Under Pressure!
Moderna won a $54.3M CEPI award to advance its mRNA‑1018 bird flu vaccine into a pivotal trial, while new FDA vaccine standards and a string of analyst downgrades have pushed MRNA shares toward 52‑week lows. This article summarizes the funding, trial plans, regulatory impact, and what investors should monitor next.
Moderna Falls After FDA Memo on Pediatric Risk
A leaked internal FDA memorandum proposing tougher vaccine approval standards and flagging potential pediatric myocarditis deaths rattled investors this week. Moderna shares fell sharply, dragging other vaccine names lower and raising questions about near-term regulatory hurdles for mRNA-based products.
Moderna Shorted Heavily; $140M Backs Norwood Build
Recent reporting shows Moderna has become one of the most heavily shorted large-cap names while simultaneously committing $140 million to complete a domestic mRNA manufacturing site in Norwood. This article explains the short-interest dynamics, the strategic manufacturing investment, and how these developments affect MRNA stock.
Moderna Boosts Liquidity; Q3 Revenue Pressures Q4!
Moderna secured a $1.5B non-dilutive credit facility, committed $140M to complete U.S. mRNA manufacturing, and reported a Q3 revenue decline with narrowed full-year guidance. These concrete actions strengthen liquidity and operational control but leave near-term revenue and profitability challenges that investors should weigh against upcoming clinical and commercial catalysts.
Moderna Hits Turbulence: Q3 Results, CMV Cut, Vote
Moderna's recent week brought a mixed signal: a Q3 revenue beat but narrower guidance, termination of the CMV program, and a shareholder vote on an option exchange that could reduce dilution. Analysts remain cautious while institutional moves show both trimming and new interest.
Moderna Gains FDA Nod; US Cancels $766M Flu Deal!!
Moderna won FDA approval for its next‑generation COVID vaccine mNEXSPIKE while the U.S. government simultaneously cancelled roughly $766M in bird‑flu vaccine contracts — a one‑two punch that produced mixed signals for MRNA stock, combining immediate commercial upside with a loss of government funding and political headwinds.